Patient information booklets

ELIQUIS® (apixaban) Patient information booklets

These booklets may be read in its electronic form (PDF) or may be printed.

If a Patient Information Booklet is printed, please ensure that:

  • It is printed in its entirety. Please do not attempt to print and use individual pages in isolation, as it has been designed to be printed in entirety
  • Its content is not edited or altered in any way
  • It is printed in colour
  • It is printed on A4 size paper
  • The pages are placed in the correct order as per the page numbering
  • ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II)1
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
  • Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery1

Footnotes:

  • NVAF = Non-Valvular Atrial Fibrillation   NYHA = New York Heart Association   TIA = Transient Ischaemic Attack   DVT = Deep Vein Thrombosis   PE = Pulmonary Embolism

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com